AOD-9604 is a small slice of human growth hormone, just 16 amino acids long. Researchers study it because it appears to keep the fat-burning side of growth hormone while leaving most of the broader hormonal effects behind.
What AOD-9604 Is
AOD-9604 stands for Anti-Obesity Drug fragment 9604. It is also called hGH Fragment 176-191, named for the part of the human growth hormone molecule it copies. A tyrosine residue is added at one end for stability, which is why some papers list it as Tyr-hGH177-191.
The compound came out of work at Monash University in Australia. The original goal was an obesity treatment that could trigger fat loss without raising growth hormone or IGF-1 levels in the bloodstream. That separation is the central idea behind the molecule.
How It Works
Full human growth hormone is a 191-amino-acid protein with many jobs. It binds the GH receptor, raises IGF-1, supports muscle growth, and influences glucose and bone metabolism. AOD-9604 keeps only the C-terminal tail, the part most linked to fat metabolism.
In fat cells, AOD-9604 appears to do two things at once. It stimulates lipolysis, the breakdown of stored fat into free fatty acids. It also inhibits lipogenesis, the storage of new fat. Together those actions push the cell toward burning fat rather than storing it.
The interesting part is what AOD-9604 does not do. It does not bind the growth hormone receptor in any meaningful way. It does not raise IGF-1. Researchers describe its action as similar to beta-3 adrenergic signaling, the same family of pathways that triggers fat breakdown during exercise or cold exposure.
Because of that separation, AOD-9604 became a useful tool for studying fat-specific effects of growth hormone. If researchers want to look at the metabolic side without the muscle, glucose, and IGF-1 changes, the fragment offers a cleaner experimental window.
Research Areas and Clinical History
Beyond fat metabolism, AOD-9604 has been studied in cartilage repair. Some preclinical work has paired it with hyaluronic acid and other regenerative compounds in joint models. The interest there is whether the fragment can support tissue maintenance without GH-receptor activation.
The clinical record for weight loss is more limited. AOD-9604 went through Phase II trials in humans for obesity. The results showed only modest effects on body weight, and the program did not advance to FDA approval. The compound is not classified as an approved drug for any indication in the United States.
That gap between mechanism and clinical impact is part of why AOD-9604 remains a research compound rather than a medicine. The cell and animal data look promising in narrow tasks, but the human translation has been hard to repeat at the level developers hoped for.
Why It Still Interests Researchers
The compound asks a useful biological question. Can a tiny fragment of a large hormone carry out one specific job without triggering the rest of the hormone's effects? AOD-9604 is one of the cleanest examples of that fragment-versus-whole approach in growth hormone research.
It also serves as a comparison tool. When researchers test other GH-related peptides or fragments, AOD-9604 helps anchor what fat-metabolic effects look like without IGF-1 involvement. That kind of control compound is valuable in mechanistic work.
Open Questions
Several questions remain. The exact receptor or signaling complex that mediates AOD-9604 activity in fat cells is still debated. The cartilage findings need larger and better-controlled studies. And the gap between strong cell-culture results and modest human trial outcomes is not fully explained.
Even with those uncertainties, the fragment continues to appear in metabolic research because of its unusual selectivity. These compounds are sold strictly for in vitro laboratory research and are not approved for human consumption.